

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
30 April 2020 (30.04.2020)



(10) International Publication Number
WO 2020/086713 A1

(51) International Patent Classification:

A61K 31/506 (2006.01) A61K 39/395 (2006.01)

A61K 31/713 (2006.01)

(21) International Application Number:

PCT/US2019/057656

(22) International Filing Date:

23 October 2019 (23.10.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/749,820 24 October 2018 (24.10.2018) US

(71) Applicant: **EFFECTOR THERAPEUTICS, INC.**
[US/US]; 11180 Roselle Street, San Diego, CA 92121 (US).

(72) Inventors: **REICH, Siegfried, H.**; 5940 La Jolla Mesa Drive, La Jolla, CA 92037 (US). **SPRENGELER, Paul, A.**; 8706 Gracilior Court, Escondido, CA 92026 (US). **WEBBER, Stephen, E.**; 3531 Millikin Avenue, San Diego, CA 92122 (US). **XIANG, Alan, X.**; 211 Midvale Lane, Irvine, CA 92620 (US). **ERNST, Justin, T.**; 4288 Kerwood Court, San Diego, CA 92130 (US). **BORER, Bennett, C.**; 4149 Lymer Dr., San Diego, CA 92116 (US). **SPERRY, Samuel**; 1247 Saxony Road, Encinitas, CA 92024 (US). **WILSON, Jo Ann, Z.**; 74 Seward Street, San Francisco, CA 94114 (US).

(74) Agent: **PINO, Mark, J.** et al.; Mintz Levin Cohn Ferris Glovsky and Popeo, P.C., 701 Pennsylvania Avenue, NW, Suite 900, Washington, DC 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,


UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

WO 2020/086713 A1

(54) Title: CRYSTALLINE FORMS OF MNK INHIBITORS



(57) Abstract: The present invention provides crystalline solids of 6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1,5'-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.